MedinCell Future Growth
Future criteria checks 6/6
MedinCell is forecast to grow earnings and revenue by 92.2% and 50.6% per annum respectively. EPS is expected to grow by 92.6% per annum. Return on equity is forecast to be 331.6% in 3 years.
Key information
92.2%
Earnings growth rate
92.6%
EPS growth rate
| Pharmaceuticals earnings growth | 17.1% |
| Revenue growth rate | 50.6% |
| Future return on equity | 331.6% |
| Analyst coverage | Low |
| Last updated | 07 Nov 2024 |
Recent future growth updates
Recent updates
MedinCell S.A. (EPA:MEDCL) Analysts Are More Bearish Than They Used To Be
Jul 05
Revenues Tell The Story For MedinCell S.A. (EPA:MEDCL) As Its Stock Soars 30%
Apr 26Market Participants Recognise MedinCell S.A.'s (EPA:MEDCL) Revenues Pushing Shares 26% Higher
Jan 09The MedinCell (EPA:MEDCL) Share Price Is Up 75% And Shareholders Are Holding On
Mar 02Is MedinCell S.A. (EPA:MEDCL) Popular Amongst Insiders?
Jan 08Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 99 | 49 | 43 | N/A | 1 |
| 3/31/2026 | 41 | 13 | 9 | 13 | 3 |
| 3/31/2025 | 24 | -10 | 5 | 1 | 4 |
| 3/31/2024 | 12 | -25 | -13 | -12 | N/A |
| 12/31/2023 | 13 | -26 | -18 | -17 | N/A |
| 9/30/2023 | 14 | -26 | -24 | -23 | N/A |
| 6/30/2023 | 14 | -29 | -23 | -22 | N/A |
| 3/31/2023 | 14 | -32 | -22 | -21 | N/A |
| 12/31/2022 | 13 | -29 | -22 | -21 | N/A |
| 9/30/2022 | 12 | -27 | -22 | -20 | N/A |
| 6/30/2022 | 10 | -26 | -23 | -21 | N/A |
| 3/31/2022 | 8 | -25 | -23 | -21 | N/A |
| 12/31/2021 | 9 | -22 | -21 | -19 | N/A |
| 9/30/2021 | 9 | -20 | -18 | -17 | N/A |
| 6/30/2021 | 9 | -19 | -15 | -14 | N/A |
| 3/31/2021 | 8 | -19 | -13 | -12 | N/A |
| 12/31/2020 | 7 | -22 | -12 | -11 | N/A |
| 9/30/2020 | 5 | -26 | -11 | -10 | N/A |
| 6/30/2020 | 6 | -25 | -12 | -11 | N/A |
| 3/31/2020 | 6 | -24 | -13 | -13 | N/A |
| 12/31/2019 | 6 | -21 | -16 | -16 | N/A |
| 9/30/2019 | 6 | -19 | -19 | -19 | N/A |
| 6/30/2019 | 5 | -19 | -18 | -17 | N/A |
| 3/31/2019 | 4 | -20 | -17 | -16 | N/A |
| 12/31/2018 | 6 | -17 | -12 | -11 | N/A |
| 9/30/2018 | 7 | -15 | -8 | -7 | N/A |
| 6/30/2018 | 8 | -12 | -7 | -6 | N/A |
| 3/31/2018 | 8 | -10 | -7 | -5 | N/A |
| 3/31/2017 | 10 | -4 | N/A | -3 | N/A |
| 3/31/2016 | 9 | 1 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MEDCL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.4%).
Earnings vs Market: MEDCL is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MEDCL is expected to become profitable in the next 3 years.
Revenue vs Market: MEDCL's revenue (50.6% per year) is forecast to grow faster than the French market (5.6% per year).
High Growth Revenue: MEDCL's revenue (50.6% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MEDCL's Return on Equity is forecast to be very high in 3 years time (331.6%).